Introduction
to suggest that low or suppressed FSH concentrations are associated with delayed age at menopause (Stanford et al., The age at menopause is likely to be a retrospective marker 1987; Cramer et al., 1995b; Sowers and La Pietra, 1995 ; Kato of the end of the fertile lifespan of women (te Velde et al., et al., 1998; Hardy and Kuh, 1999) . Since OCs also suppress 1998a). The factors that influence age at menopause are FSH concentrations, long lasting use of OC may also delay therefore also likely to determine the age at which preceding age at menopause. reproductive events occur, such as the beginning of subfertility
The few studies that included the effect of OC use in their and the end of fertility. According to Richardson (1993) , the design found either a delaying effect of OC use on age at transition from regular menstruation to the peri-menopause, menopause (Van Keep et al., 1979; Stanford et al., 1987) or with irregular cycles, and the subsequent transition to menono effect (Brambilla and McKinlay, 1989; Cramer et al., pause are mainly determined by the size of the residual follicle 1995b; Bromberger et al., 1997; Van Noord et al., 1997) . pool (Richardson, 1993) . The size of the follicle pool is However, most studies failed to exclude women who used determined by the woman's initial number of oocytes, and by hormone replacement therapy (HRT) or OCs for menothe rate at which these oocytes are lost. It is generally accepted pausal complaints, leading to a potentially spurious positive that FSH has a predominant role in the late stages of follicular association between OC use and menopausal age. development (Gougeon, 1996; te Velde et al., 1998b) . It is Studies addressing the relationship between the use of high still a matter of debate whether high FSH concentrations dose OCs and menopausal age are lacking. High dose OCs accelerate the depletion of the follicle pool, by stimulating strongly suppress FSH concentrations because of their high resting follicles to start growing (Kumar et al., 1997 In this cohort study, we investigated the effect of OC use Netherlands, the first tablets containing oestrogens and progestins on menopausal age. We were able to use a cohort of a large (lynestrenol) were introduced in 1962, officially only for treatment number of women (n ϭ 8701), 3242 of whom reported that of disturbances of the menstrual cycle. Based on market information they used high dose OCs.
it was estimated that in the Utrecht region prior to 1972, high dose (Ͼ50 µg oestrogen) OCs were predominantly prescribed (Haspels and Kay, 1982) . Duration of high dose OC use was defined as the sum of years before 1972 in which a woman used OCs for at least 3 Materials and methods months (van Hoften et al., 2000) .
Population
Exclusion and inclusion criteria From January 1982 to April 1985 all women born between 1932 and 1941 and living in Utrecht or one of the 22 smaller municipalities in Subjects who used HRT or OCs for menopausal symptoms during the province of Utrecht, The Netherlands, were invited to participate the 4 years prior to the date of last menstruation or the first year in a breast cancer screening programme (de Waard et al., 1984) . Of following the last menstruation (n ϭ 3477) were excluded from the these women 12178 women participated and they became known as analyses, because these women can have withdrawal bleedings caused the DOM-3 cohort. (DOM is short for 'Doorlopend Onderzoek by the use of OCs or HRT, obscuring the date of the menopause. Morbiditeit/Mortaliteit'). The women filled out a self-administered
Of the women included in the analyses (n ϭ 8701), age at natural questionnaire on medical history, use of OCs, use of HRT for menopause was known in 4523 cases (1076 of whom were postmenopausal symptoms, smoking, reproductive history, menopausal menopausal at their initial screening visit), 4178 women were censored status, age at menopause, surgery that caused cessation of menses, at the age of their last known menstruation because they did not and health insurance. The women were asked to mark on a calendar experience a natural menopause. Of these censored women, 2466 the years in which they had used OCs for at least 3 months.
women had undergone surgery that caused cessation of menstruation, Women were defined as being post-menopausal if their menses 1547 were still pre-menopausal when they were lost to follow-up and had been absent for at least 12 months due to factors other than 165 women were pre-menopausal in the questionnaire from 1995. pregnancy or lactation; all of the other women were defined as premenopausal. Women who were still considered pre-menopausal at Confounders their initial screening visit were sent a postal questionnaire in 1986, Smoking, parity, body mass index (BMI), socio-economic status and comprising questions about the date of their previous menstrual period possibly age at menarche are related to menopausal age, and were and the use of HRT or OCs for menopausal symptoms during the therefore considered as potential confounding variables. Current past 4 years. If women had undergone a medical treatment that caused smoking was defined as having smoked cigarettes regularly during cessation of menstruation, they were asked what kind of treatment the past year and past smoking was defined as having smoked more this was. They were also asked to keep their menstrual data on a than a year ago. Socio-economic status is based on the type of health calendar sent along with the questionnaire. Women who were still insurance, whether public health insurance, which is government pre-menopausal were sent a similar questionnaire in 1987, 1989, mandated (lower status), civil servants insurance (intermediate 1992, 1993 and 1995. Response was about 80% each year. Both status) or private insurance (higher status). Trained medical assistants women who responded and those who did not respond in early 1986 measured height and weight at the screening. BMI was calculated were sent a questionnaire in late 1987. But women not responding using the formula [weight (kg)/height (m) 2 ]. The year of birth was in 1987, 1989 and 1991 were not sent a questionnaire in 1989, 1991 also included in the analyses to check for any discrepancies in variable and 1993 respectively. We made special efforts to complete the characteristics among the different age groups. follow-up for a random sub-sample of 4207 women in 1992. We found the new addresses of women who had moved via municipal Statistical analyses administrations. All women who had failed to respond to one of the Kaplan-Meier estimates were used to compare failure time distribuprevious questionnaires were sent a questionnaire again and those tions for the categories in each risk factor. Log-rank tests were carried still not responding were approached by telephone. After these efforts out to test the differences in failure time distributions. The endpoint follow-up for this subsample was 90% complete. For the total cohort of the analyses was natural menopause (failure). Cessation of the follow-up is 82% complete. menstruation due to other causes and loss to follow-up were censoring events. The biological age of the participating women was on the Menopausal age time axis.
To obtain estimates of the hazard ratio (HR) for each variable and The date of menopause was the last date of menses, defined retrospectively following 12 months of amenorrhoea. Age at menofor each variable adjusted for all potential confounders we used Cox's proportional hazard models. These models predict the ratio of pause was computed by subtracting the date of birth from the date of the onset of menopause. For women who were post-menopausal incidence rates as the dependent variable: the hazard ratio. This ratio is assumed to be constant over time (proportional hazards) (Rothman, at their screening visit (n ϭ 1076), the exact date of menopause was not known. The questionnaire filled out at screening provided data 1986). This assumption of proportional hazards was checked for each variable by making log-minus-log plots. The assumption was found on menopausal age (in years), not the exact date (day, month, year) of their last menstruation. Therefore, only truncated menopausal ages to be justified for all variables. of entering menopause than nulliparous women. The more children a woman has given birth to, the later she will enter menopause. Women who currently smoke will reach Results menopause at an earlier age than women who have never The overall estimated median age at menopause is 51 years smoked or used to smoke. Women with a BMI ഛ27 will reach (average 50.82). From the Kaplan-Meier estimates, there is menopause earlier than women with a BMI Ͼ27 and women no clear indication that OC use influences menopausal age.
with a low socio-economic status will experience an earlier There is evidence of a difference in menopausal age due to menopause than women with a higher socio-economic status. parity, smoking, BMI, type of health insurance and year of
The younger birth cohort of women has a decreased risk of birth, as indicated by the log-rank tests (Table I) . Duration entering menopause compared with the older birth cohorts in of use of high dose OCs for 3 or more years and a total use this study. In our data, age at menarche was not associated of 11 or more years of any type of OC does not significantly with age at menopause and, as expected, was also not a influence age at menopause (unadjusted HR ϭ 1.07; 95% CI confounder in the association between OC use and menopausal 0.99-1.15 and HR ϭ 1.10; 95% CI 0.99-1.22 respectively, age (data not shown). Therefore, age at menarche was not Table I) .
included in the final analyses. Table II shows adjusted hazard ratio's for risk factors
The linear regression analyses show that for each year of included in the study. After taking into account all other risk high dose OC use, age at menopause decreased by 1.2 months (P Ͻ 0.001). factors, the long-term (ജ3 years) use of high dose OCs and Tests for trend showed the existence of a significant linear dominantly women with signs of early ovarian ageing (irregularity of cycles). These women were expected to enter trend for years of high dose OC use (P Ͻ 0.005) and total menopause at an earlier age than women without signs of years of OC use (P Ͻ 0.005) with menopausal age. early ovarian ageing. However, as women who used OCs in the 4 years prior to menopause were excluded from our Discussion analyses, we find it unlikely that such a selection will have Before interpreting the results of this study, some issues need substantially influenced our results. In addition, it is very likely to be addressed. The excluded group of women (women who that physicians often prescribed these OCs for contraceptive used OCs or HRT around the date of their last menstruation) purposes, despite the fact that this was officially prohibited (n ϭ 3477) did not differ from the included group with respect until 1969. The population-based design of our study is an to most of the variables, except that they generally had a later advantage, as we did not examine a selected group of women. self-reported menopause, as expected. The excluded women
We were able to collect data from a large number of women were also somewhat younger and had had fewer hysterectomies (n ϭ 8701), making it easier to find subtle effects of potential and/or ovariectomies. Quite a few women were lost to follow risk factors on menopause. up (n ϭ 1547). Although we cannot exclude the possibility of Our cut-off point for high dose OC use is somewhat arbitrary. selective loss to follow-up, this seems unlikely as this group Before 1972, lower dose OCs were already being prescribed of women does not differ in the distribution of variables other and after 1972, some women were still using high dose than that they were generally younger than the other women.
OCs. Different manufacturers introduced new types of OCs It is possible that the effect of high dose OCs is due to the throughout the years and used different doses and types of fact that in The Netherlands, from 1962-1969, OCs were oestrogens and progestins in their products. The possibility of officially only registered to treat disturbances of the menstrual mis-classification of women using high dose OCs is present. cycle and not for contraceptive purposes. Therefore, it is
We were obliged to use this cut-off point because the individual data about the type of OC women used is not known. By possible that women who used high dose OCs were pre-using the market information we were able to estimate the Experimental findings and observations clearly show that follicles are able to grow without the presence of gonadotroeffect of long-term use of high dose OCs, despite the fact that the individual data was missing.
phins (Kumar et al., 1997; Dierich et al., 1998; Parrott and Skinner, 1999) . It is understandable therefore, that follicle In this study, the date of menopause for most women was determined prospectively (n ϭ 3447). Relatively few women growth until the selectable stage was considered to be a gonadotrophin-independent process (Wandji et al., 1997) . Howwere already menopausal at their screening visit (n ϭ 1076). For these women age at menopause was determined retrospecever, there is growing evidence indicating that in complex cooperation with other factors, FSH facilitates the initiation of tively. However, the date of their last menstruation was relatively recent, reducing the possibility of recall errors. follicular growth and stimulates early follicular development (te Velde et al., 1998b) . Moreover, there is strong evidence We confirmed all known effects for the other variables included in our analyses (Sowers and La Pietra, 1995;  Kato that the actual resting follicle pool does not only contain primordial follicles but also intermediate and primary follicles et al., 1998; Hardy and Kuh, 1999) . This point is reassuring regarding the validity of our study. Although we adjusted for (de Bruin et al., 2001) . Only thereafter does transition to the rapid growth phase commence. The fact that FSH receptors possible confounders, the possibility of residual confounding by smoking and socio-economic status cannot be excluded.
have been demonstrated in the granulosa cells of primary follicles (Oktay et al., 1997 ) is in agreement with the possible Our main finding is that long-term users of high dose OCs (Ͼ50 µg oestrogen for 3 or more years) experience menopause role of FSH during the transition from the resting follicle pool to the growth phase. at a slightly younger age compared with women who did not use OCs or only used lower dose OCs (ഛ50 µg oestrogen).
Our investigation was based on the hypothesis that menopause can be delayed by sparing resting follicles. If FSH Use of lower dose OCs has no influence on age at menopause.
Eleven or more years of total OC use advanced menopausal stimulates the initiation of growth of these resting follicles, then this would mean that very low concentrations or the age. However, this is probably due to the effect of long-term use of high dose OCs. Our results are in contradiction with absence of FSH would inhibit this initiation and thereby delay menopause. This hypothesis is partly confirmed by studies in the results of most other studies investigating the influence of OCs on menopausal age. These studies either found no effect which it was observed that FSH-suppressing factors, such as parity and irregular or long menstrual cycles, can delay age at on menopausal age (Brambilla and McKinlay, 1989; Cramer et al., 1995b; Bromberger et al., 1997; Van Noord et al., 1997) menopause (Cramer et al., 1995b; Sowers and La Pietra, 1995; Van Noord et al., 1997; Kato et al., 1998 ; Hardy and or a postponement of menopause with OC use (Van Keep et al., 1979; Stanford et al., 1987) . An investigation into the Kuh, 1999) . OC use suppresses FSH concentrations, therefore it was influence of OC use on peri-menopausal age, indicated the existence of a (nonsignificant) trend for earlier inception of hypothesized that long-term OC use, in particular long-term high dose OC use, would postpone menopause to a later age. peri-menopause with long-term OC use (Hardy and Kuh, 1999) . This result is consistent with our findings.
The results of our analyses contradict this hypothesis: longterm use of high dose OCs does not delay menopause, it The majority of studies, with the exception of just two (Bromberger et al., 1997; Hardy and Kuh, 1999) , did not actually accelerates the onset of menopause. Our finding may be explained by the findings of other studies (Gougeon, 1996) exclude women who used HRT or OC for menopausal symptoms from their analysis. In our study we have excluded this stating that the absence of FSH increases levels of oxidative free radicals in granulosa cells. This in turn causes the group of women, because dates of natural menopause can be obscured by bleedings caused by OC use or use of HRT. activation of endonucleases, thereby initiating apoptosis of follicles. Our findings may also be explained by the fact that None of the studies mentioned made a distinction between different types of OCs or took into account a dose-response exogenous progesterone can have a damaging effect. It was found that mice who had been exposed to exogenous relation. Some studies did not adjust for other variables influencing menopausal age, such as smoking and parity. Our progesterone showed increased atresia of antral follicles (Telfer et al., 1991) . In addition, a study on the methods of initiation univariate results also showed no effect of OC use; the effect of OCs became apparent only after adjustment for other of primordial follicle development in rats in vitro (Parrott and Skinner, 1999) showed that primordial follicles develop into variables.
As in previous reports, parity and a high BMI increased age primary follicles in medium with no factor added. Treatment of ovaries with gonadotrophins inhibits this spontaneous at menopause, whilst smoking decreased age at menopause (Cramer et al., 1995a,b; Sowers and La Pietra, 1995 ; Kato development of primordial follicles into primary follicles. If this is also the case in vivo in humans, OC use could accelerate et al., 1998; Nagata et al., 1998; Hardy and Kuh, 1999) . We have found a decreased risk of menopause in the cohorts of the depletion of the follicle pool by lowering gonadotrophin concentrations, thereby allowing the spontaneous development younger women. This is probably due to an age-related artefact: these cohorts simply have not yet had the same chance of of primordial follicles into later stages of follicle development. The fact that we did not observe any effect on menopausal being menopausal as the cohort of older women in this study.
The predominant role of FSH in the late stages of follicular age in lower dose OCs might be explained by the fact that lower doses of oestrogens and progestins suppress FSH development is extensively investigated and generally accepted (Gougeon, 1996) . In contrast, the reason why follicles start concentrations in a more moderate way (Copeland, 1993 ).
In conclusion, the effect of OC use found in this study is to grow after many years of dormancy is still a mystery.
